Anti-infective skin replacement therapy - StratatechAlternative Names: ExpressGraft™ - Anti-microbial; ExpressGraft™ - C9T1; NIKSC9T1
Latest Information Update: 02 Feb 2017
At a glance
- Originator Wisconsin Alumni Research Foundation
- Developer Stratatech
- Class Cell therapies
- Mechanism of Action Cathecilidin expression stimulants; Tissue replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Varicose ulcer
- Preclinical Diabetic foot ulcer